Pneumonia Due to Stenotrophomonas Maltophilia in ICUs

NCT03506191 | Unknown

• 1 other identifier: RETROSTENO
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 4

Brief Summary

Pneumonia is a major cause of ICU admission, or may complicate ICU course. Among the causative pathogens, Stenotrophomonas Maltophilia is a rare pathogen, but affects usually patients with chronic pulmonary co-morbidities, or with long duration of mechanical ventilation and multiples treatment with broad spectrum antimicrobial therapy. However, there are only a paucity of data regarding epidemiology, impact and outcome of Pneumonia due to Stenotrophomonas Maltophilia in critically ill patients. Primary objective was to study factors associated with mortality in case of Pneumonia due to Stenotrophomonas Maltophilia. Secondary objectives were to describe factors associated with morbidity of Pneumonia due to Stenotrophomonas Maltophilia (duration of mechanical ventilation, ICU length of stay), and to report the characteristics of critically ill patients presenting Pneumonia due to Stenotrophomonas Maltophilia.

Conditions

Pneumonia, Ventilator-Associated; Stenotrophomonas Infection; Critical Illness; Pneumonia, Bacterial

Keywords

Stenotrophomonas maltophilia; Pneumonia; Intensive Care Unit

Outcome Measures

Primary Outcomes (1)

• Treatment failure

  Treatment failure is defined as composite of death and recurrence of pneumonia due to Stenotrophomonas Maltophilia within 30 days of the first episode

  Day 30

Secondary Outcomes (3)

• Duration of mechanical ventilation

  Day 30

• Recurrence of pneumonia due to Stenotrophomonas Maltophilia

  Day 30

• Mortality

  Day 30

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients hospitalized in Intensive Care Unit and presenting pneumonia due to Stenotrophomonas maltophilia

You may qualify if:

• Patients older than 18 years
• Documented Stenotrophomonas maltophilia pneumonia:
• Clinical suspicion (≥ two criteria including: fever\> 38.5°C, leukocytosis \> 10\^9/L or leukopenia \< 4.10\^8/L, purulent tracheobronchial secretions and a new or persistent infiltrate on chest radiography).
• Documented Stenotrophomonas maltophilia positive quantitative culture of a respiratory sample: bronchoalveolar lavage fluid (significant threshold, \>10\^4cfu/ml) or plugged telescopic catheter (significant threshold, \>10\^3cfu/ml) or quantitative endotracheal aspirate (significant threshold, \>10\^6cfu/ml).

You may not qualify if:

• None

Sponsors & Collaborators

• Groupe Hospitalier Pitie-Salpetriere: lead

Study Sites (4)

Réanimation Polyvalente CHR Metz-Thionville

Metz, France

Location

Department of Anesthesiology and Critical Care Medicine, University Hospital of NANCY

Nancy, 54500, France

Location

Department of Anesthesiology and Critical Care Medicine, University Hospital of Strasbourg

Strasbourg, France

Location

Anesthesiology and Critical Care Medicine, Groupe Hospitalier Pitié-Salpêtrière

Paris, Île-de-France Region, 75013, France

Location

Related Publications (1)

• Guerci P, Bellut H, Mokhtari M, Gaudefroy J, Mongardon N, Charpentier C, Louis G, Tashk P, Dubost C, Ledochowski S, Kimmoun A, Godet T, Pottecher J, Lalot JM, Novy E, Hajage D, Bougle A; AZUREA research network. Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study. Crit Care. 2019 Nov 21;23(1):371. doi: 10.1186/s13054-019-2649-5.

  PMID: 31752976 DERIVED

MeSH Terms

Conditions

Pneumonia, Ventilator-Associated; Critical Illness; Pneumonia, Bacterial; Pneumonia

Condition Hierarchy (Ancestors)

Healthcare-Associated Pneumonia; Cross Infection; Infections; Respiratory Tract Infections; Lung Diseases; Respiratory Tract Diseases; Iatrogenic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bacterial Infections; Bacterial Infections and Mycoses

Study Officials

• Adrien Bouglé, MD

  APHP

  STUDY DIRECTOR

• Philippe Guerci, MD

  CHRU NANCY

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Study director

Study Record Dates

• First Submitted: April 13, 2018
• First Posted: April 24, 2018
• Study Start: January 1, 2017
• Primary Completion: July 30, 2018
• Study Completion: September 30, 2018
• Last Updated: August 1, 2018

Record last verified: 2018-07

Locations

FR (4)